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E-mail address: stoccogc@unipa.it (G.C. Stocco).Three novel cisplatin analogues were synthesized, designed according to an approach which violates
the ‘‘classical’’ structure–activity relationship, by replacing the diamine ligands with a planar N donor
heterocycle giving a sterically hindered complex. Moreover, the sterical hindrance of antitumor drug
candidates potentially makes them less susceptible to deactivation by sulphur-containing proteins
and helping to overcome resistance mechanisms. The resulting mononuclear complexes of sterically
hindered polidentate heterocyclic N ligands [PtCl(bbp)]Cl (1) [bbp = 2,6-bis(2-benzimidazolyl)pyridine],
[PtCl2(dptdn)](H2O) (2) [dptdn = sodium 5,6-diphenyl-3-(20-pyridyl)-1,2,4-triazine-400 ,400 0-disulfonate]
and [(dptdn)(dpt)Pt]Cl2(H2O) (3) [dpt = 5,6-diphenyl-3-(20-pyridyl)-1,2,4-triazine] have been prepared
and structurally characterised. Both neutral and ionic complexes are present, with monofunctional
(1) and bifunctional Pt(II) moieties (2) and coordinatively saturated Pt(II) ions in the mixed ligand com-
plex (3), whose size and shape enable them to behave as novel scaffolds for DNA binding. All complexes
were tested ‘‘in vitro’’ for their biological activity on human HT29 colorectal carcinoma and HepG2 hep-
atoma cells. The complexes (1) and (3), endowed with a positive charge, showed a potent cytotoxic
activity and reduced cell viability with an efﬁcacy higher than that of cisplatin; whilst the neutral
bifunctional compound (2) was inactive. IC50 values have been calculated for the active compounds.
The cytotoxic effects were conﬁrmed by the accumulation of treated cells in subG0/G1 phase of cell
cycle, by the loss of mitochondrial potential (Dwm) and by the chromatin condensation or fragmenta-
tion observed by means of ﬂuorescence microscopy after Hoechst 33258 nuclear staining. A study on
intracellular platinum uptake in HT29 cell line has been also performed and data obtained strongly
suggest that the cytotoxicity of new tested complexes reported in this work is based on a different
pharmacodynamic pattern with respect to cisplatin.
 2011 Elsevier B.V. All rights reserved.1. Introduction Tethering carbohydrate moieties to the platinum centre [1], wasHuge limitations due to lack of activity against tumours with
inherent or acquired resistance to cisplatin along with a variety
of adverse effects, such as nephrotoxicity, myelosupression, and
severe emesis have been observed [1,2]. New approaches in design
and development of platinum complexes to overcome drug resis-
tance and increase the range of drug activity include replacement
of chloride ligands with various leaving groups, use of modiﬁed
amine and non-amine ligands to form polynuclear platinum
complexes and combination therapy using both platinum and
ruthenium has been advanced [3]. Cisplatin stands as a milestone
of biological activity of metal ions and the usefulness of providing
more advances in this prominent ﬁeld is not farfetched.
Interest in mononuclear cisplatin analogues has improved as a
strategy for selective delivery of platinum anticancer agents.ll rights reserved.
: +39 091 427584.designed to target liver cancer because of galactose receptors on
the surface of liver parenchymal cells. DNA targeting moieties such
as DNA intercalators used as platinum carriers may also be a new
strategy, possibly leading to a broadened spectrum activity [4] and
exalting platinum intracellular uptake. Pt(II) complexes with poly-
pyridyl 2-(2-benzimidazolyl)pyridine ligands [5], heterocycles
endowed with hydrophobic properties, have been reported and
an increase of hydrophobicity around the drug-DNA binding site
has been assessed. The presence of NH containing moieties in these
complexes can originate H-bonding interactions towards DNA, val-
idating the well-established structure–activity relationships which
claims the necessity of at least one NHmoiety within the ligand for
H-bonding interactions towards DNA. In this paper we report a
platinum complex of this ligand which is very active towards
two cancer cell lines. A cisplatin analogue with 5,6-diphenyl-3-
(20-pyridyl)-1,2,4-triazine-400,400 0-disulfonate, lacking the N–H
group, has been obtained, which is inactive. The same ligand along
with 5,6-diphenyl-3-(20-pyridyl)-1,2,4-triazine was used to afford
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the cited cell lines. The antitumor activity of the complexes lacking
a NH containing moiety may be the concomitant intercalation and
the presence of increased steric hindrance around the coordinated
platinum atom as the complex cannot be easily inactivated by
biomolecules as S-containing proteins before binding to DNA [6].
Platinum(II) complexes with N-donor aromatic 3-(pyridyl-20-yl)-
1,2,4-triazine ligands have been reported to possess great potential
as anti-HIV microbicides [7]. Amongst the complexes presented in
this work the one which bears the closest similarity to cisplatin is
[PtCl2(dptdn)] 2 which is neutral and bifunctional, to our dismay
being inactive, whilst complexes 1 and 3 appear to be endowed
with very high biological activity.2. Experimental
2.1. Materials and methods
Potassium tetrachloro platinate(II) and the ligands sodium 5,6-
diphenyl-3-(20-pyridyl)-1,2,4-triazine-400,400 0-disulfonate (dptdn)
and 2,6-bis(2-benzomidazolyl)pyridine (bbp) were purchased from
Aldrich.
Syntheses were performed with exclusion of moisture and di-
rect light. Compounds were analysed for C, H, N at the Laboratorio
di Microanalisi (Università degli Studi di Padova, Italy), chlorine
was determined by potentiometric titration with standard silver
nitrate after combustion in pure oxygen according to Schöninger
[8].
Thermogravimetric measurements were performed from room
temperature to 500 C, with a Mettler TA-4000 system operating
in a pure nitrogen atmosphere. The IR spectra were recorded, as
Nujol mulls, with a Model Spectrum ONE Perkin–Elmer Fourier
Transform Instrument. Conductivity measurements for 103 M
solutions in DMSO were obtained with a Crison GLP 31 Model con-
ductometer. Conductivity measurements on freshly prepared sam-
ples showed no evidence of signiﬁcant irreversible solvolysis of
platinum groups since only the ionic complexes 1 and 3 showed
conductivity. The determination of potassium and platinum
contents were obtained using a ﬂame atomic spectrometer Per-
kin–Elmer 372 and the reported value is the average of four inde-
pendent measurements. Platinum up-take determination was
performed with an graphite furnace atom absorption spectrometer
(GFAA) from Perkin–Elmer. A mechanistic study of mode of action
of the complexes in water (kinetics of hydrolysis) was prevented
by their insolubility in water.
The very poor solubility of complexes made it necessary to
record the NMR spectra in DMSO-d6 1 D and 2 D 1H and 13C {1H}
NMR spectra for the Pt(II) derivatives were obtained at 298 K with
Bruker Avance 300 instrument operating at 300 MHz for 1H and at
63 MHz for 13C, in DMSO-d6 with tetramethylsilane (TMS) as the
internal standard; furthermore, to facilitate the assignments,
1H–1H COSY (H,H correlated spectroscopy) experiments were car-
ried out.
The most interesting feature of the NMR spectra is the indica-
tion of which sites are involved in platination. Assignment of reso-
nances was based on literature data [9–11] and are in good
agreement with the proposed structure. The solvated complex 1
presented a dismally low solubility even in DMSO-d6 which pre-
vented the acquisition of 13C NMR spectra.2.2. Chemical synthesis
2.2.1. Synthesis of [PtCl(bbp)]Cl complex (1)
An aqueous solution of K2PtCl4 (0.8317 g, 2 mmol) was treated
with a solution of 2,6-bis(2-benzimidazolyl)pyridine (bbp)(0.6256 g, 2 mmol) obtained by using a mixture of ethanol (5 ml)
e H2O (20 ml). The ligand was sparingly soluble in the mixed sol-
vent so NaOH 0.1 M was added and the pH was carried to 8. The
mixture was maintained under reﬂux for four days in the dark.
The red-brown solid complex 1 was ﬁltered, washed with water,
methanol and dried over P4O10. Yield: 70%. Anal. Calc. for
C19H13N5PtCl2: C, 39.53; H, 2.27; N, 12.13; Cl, 12.28, Pt, 33.79.
Found: C, 40.00; H, 2.53; N, 12.50; Cl, 12.71, Pt, 34.00%. Melting
point: >350 C (decomp.). The complex is sparingly soluble in
DMSO.
Conductivity measurements of the complex for a 103 M solu-
tion in DMSO afforded a value of KM = 34.86X1 cm2 mol1 which
was consistent with a 1:1 electrolyte [12].
IR (cm1) selected bands: 318 cm1 m(Pt–Cl), 3500–3065 cm1
m(N–H).
1H NMR spectrum for free ligand bbp (d ppm): 13.06 (s, 2H, N–
H), 8.42 (d, 2H, HF–HH), 8.23 (t, 1H, HG), 7.82 (d, 4H, HA–HD), 7.40
(m, 4H, HB–HC). 1H NMR spectrum for the complex 1: 10.16 (s,
2H, N-H), 8.40 (d, 2H, HF–HH), 8.30 (dd, 1H, HG), 7.80 (q, 4H, HA–
HD), 7.45 (q, 4H, HB–HC). J3HF,HH–HG = 7.5; J3HA,HD–HB,HC = 3.3.
2.2.2. Synthesis of [PtCl2(dptdn)](H2O) complex (2) and
[(dptdn)(dpt)Pt]Cl2(H2O) (3)
Complex 2: A slight excess of K2PtCl4 (0.415 g, 1.00 mmol) in
water was added dropwise with stirring to a solution of sodium
5,6-diphenyl-3-(20-pyridyl)-1,2,4-triazine-400,400 0-disulfonate (dptdn)
(0.4705 g, 0.9145 mmol) in H2O (25 mL), under reﬂux for 24 h in
the dark after addition of 1 ml HCl 0.969 M. A brown solid complex
2 was ﬁltered, washed with ethanol and dried over P4O10. Yield:
80%. Anal. Calc. for C20H15N4O7S2PtCl2K: C, 30.31; H, 1.91; N,
7.07; S, 8.09; Cl, 8.95; K, 4.93, Pt 24.61. Found: C, 29.95; H, 1.58;
N, 7.04; S, 8.59 Cl, 8.55, K, 5.31; Pt 25.10%. Melting point:
>350 C (decomp.). The complex is soluble in DMSO. Thermogravi-
metric analysis conﬁrmed the occurrence of 1 mol of H2O per
formula unit. Conductivity measurements of the complex for a
103 M solution in DMSO afforded a value of KM = 6.79 X1 cm2
mol1associated with a neutral complex [12].
Complex 3: An aqueous solution of K2PtCl4 (0.3112 g,
0.749 mmol) was added to a mixed methanol–water solution
(5:1, v/v) of 5,6-diphenyl-3-(20-pyridyl)-1,2,4-triazine (dpt)
(0.2331 g, 0.749 mmol) and sodium 5,6-diphenyl-3-(20-pyridyl)-
1,2,4-triazine-400,400 0-disulfonate (dptdn) (0.3670 g, 0.749 mmol)
with stirring under reﬂux for 24 h in the dark. A greenish solid
complex 3 was collected, washed with water and methanol fol-
lowed by anhydrous diethyl ether, dried over P4O10. Yield: 90%.
Anal. Calc. for C40H29N8O7NaS2PtCl2: C, 44.21; H, 2.69; N, 10.31;
Cl, 6.52, S, 5.9; Na, 2.12, Pt, 17.95. Found: C, 43.85; H, 2.15; N,
9.81; Cl, 6.71; S, 5.14; Na, 2.0; Pt, 17.58%. Melting point: >350 C
(decomp.). The complex is sparingly soluble in DMSO. Thermo-
gravimetric analysis conﬁrmed the occurrence of 1 mol of H2O
per formula unit. Conductivity measurements of the complex for
a 103 M solution in DMSO afforded a value of
KM = 30.20X1 cm2 mol1 which was consistent with a 1:2 elec-
trolyte [12], that could be explained with low ionic mobility of
the ionic moiety.
IR (cm1) selected bands for complex 2: 310–360 cm1 m(Pt–
Cl); 540–550 cm1 m(Pt–N); 535 cm1 (rocking SO3H, SO3);
1121–1215 cm1 (stretching SO3H, SO3); 1570–1609 cm1
m(C@N) and m(N@N). 1H NMR spectrum for the free ligand dptdn
(d ppm): 8.94 (d, 1H, H6’); 8.80 (d, 1H, H30); 8.42 (dt, 1H, H40);
8.34 and 8.21 (s, 1H, SO3H), 7.93 (dt, 1H, H50), 7.74–7.28 (m, 10H,
phenyl protons). 1H NMR spectrum for complex 2 (d ppm): 10.49
(d, 1H, H60); 9.71 (d, 1H, H30), 8.93 (m, 1H, H40); 8.76 (td, 1H, H50),
8.43 (s, 1H, SO3H), 7.94–7.69 (m, 10H, phenyl protons).
J3H60 ,H50 = 4.2; J3H30 , H40 = 8.2; J3H50 , H40 = 8.0. 13C {1H} NMR for the
complex 2 (d ppm): 157.86 (C3), 157.25 (C6), 156.47 (C5), 149.03
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(phenyl carbons).
IR (cm1) selected bands for complex 3: 542 cm1 (rocking
SO3H, SO3), 1121–1215 cm1 (Stretching SO3H, SO3); 1597–
1630 cm1 m(C@N) and m(N@N); 3500 cm1 (H2O). 1H NMR spec-
trum for the free ligand dpt (d ppm): 9.01 (d, 1H, H60); 8.74 (d,
1H, H30), 8.28 (dt, 1H, H40); 8.83 (m, 1H, H50), 7.74–7.61 (m, 10H,
phenyl protons). 1H NMR spectrum for complex 3 (d ppm): 10.40
(d, 1H, H60); 10.20 (d, 1H, H30), 9.60 (t, 1H, H40); 8.98 (d, 1H, H50),
8.68 (s, 1H, SO3H), 8.90–7.51 (m, 10H, phenyl protons). J3H60 ,H50 =
4.2; J3H30 , H40 = 7.8; J3H50 , H40 = 7.5. 13C {1H} NMR for the complex 3
(d ppm): 160.37 (C3), 156.86 (C6), 156.39 (C5), 152.25 (C60),
150.03 (C20), 138.65 (C30) 135.75 (C40),135.64 (C50), 131.08–124.49
(phenyl carbons).
2.3. Biological studies
2.3.1. Chemicals and reagents
Stock solutions of the compounds were prepared in DMSO and
opportunely diluted in the culture medium. The ﬁnal concentration
of DMSO never exceeded 0.1% that is a concentration which had no
discernible effect on employed cell lines in comparison with the
control.
2.3.2. Cell lines and culture conditions
Human colon–rectal carcinoma HT29 and hepatoma HepG2
cells were grown as monolayers in RPMI 1640 medium, supple-
mented with 10% (v/v) heat-inactivated foetal calf serum (FCS)
and 2.0 mM glutamine, at 37 C in a humidiﬁed atmosphere con-
taining 5% CO2. HepG2 culture medium also contained 1.0 mMFig. 1. Structure of [PtCl(bbp)]Cl complex
Fig. 2. Structure of [PtCl2(dptdn)](H2O) compsodium pyruvate. The cells were seeded on 96-well plates
(104 cells/well) for viability assay, and in 6-wells plates
(3  105 cells/wells) for ﬂow cytometry and platinum uptake. After
plating, cells were allowed to adhere overnight and then treated
with the compounds or with the same amount of DMSO employed
as vehicle for the Pt complex treatment (control cells).2.3.3. Cell viability assay
The cytotoxic activity of the compounds was determined by the
MTT quantitative colorimetric assay [13] capable of detecting via-
ble cells. This method is based on the reduction of the 3-(4,5-di-
methyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
into purple formazan by mitochondrial dehydrogenases of living
cells. Dye absorbance in viable cells was measured at 570 nm (test
wavelength) with 630 nm (reference wavelength), using an ELISA
microplate reader (OPSYS MR, Dynex Technologies) against lysis
buffer as a blank. Cell survival was estimated as a percentage of
the value of the vehicle-treated control.2.3.4. Cell cycle analysis
The cell cycle phase distribution was evaluated by cytoﬂuori-
metric analysis. After treatment with the compounds, cells were
harvested by trypsinization and resuspended in a hypotonic solu-
tion containing 50 lg/ml propidium iodide, 0.1% sodium citrate,
0.01% Nonidet P-40 and 10 lg/ml RNase A and incubated for 2–
3 h at 4 C. The cell cycle proﬁles were analysed by Epics XL ﬂow
cytometer (Beckman Coulter) using Expo32 software. Percentage
of cells in the subdiploid region was considered as an index of
apoptosis.(1) and numbering scheme of atoms.
lex (2) and numbering scheme of atoms.
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Mitochondrial transmembrane potential (Dwm) was measured
by using 3,3-dihexyloxacarbocyanine (DiOC6 Molecular Probes,
Eugene, OR), a lipophilic cationic ﬂuorochrome which exclusively
emits within the spectrum of green light and accumulates in the
mitochondrial matrix under the inﬂuence of Dwm. After treatment,
cells were incubated with 40 nM DiOC6 for 20 min at 37 C, washed
twice with PBS and analysed by ﬂow cytometry on Beckman
Coulter Epics XL ﬂow cytometer with excitation and emission
setting of 488 and 525 nm, respectively. The percentage of cells
showing a lower ﬂuorescence, reﬂecting loss of mitochondrial
transmembrane potential, was determined by comparison with
untreated control using Expo32 software. Carbonyl cyanide
m-chlorophenylhydrazone (CCCP, 50 lM), a protonophore which
completely de-energises mitochondria by dissipating the trans-
membrane potential, was used as a positive control for maximum
Dwm disruption (not shown).2.3.6. Hoechst staining
Chromatin condensation was detected by nuclear staining with
Hoechst 33258. The cells were seeded in 96-well plates, ﬁxed with
ice-cold MeOH/AcOH 3:1 for 10 min at room temperature, washed
in phosphate buffer saline (PBS) and stained for 10 min in PBS con-
taining 40% paraformaldehyde and 10 lg/ml Hoechst 33258 in the
dark for 10 min. After staining, the samples were observed under a
ﬂuorescence microscope equipped with an automatic photomicro-
graph system (Leica, Germany).Fig. 3. Structure of [Pt(dptdn)(dpt)]Cl2(H2O) com2.3.7. Total cellular platinum uptake measurement
For platinum uptake studies [14], HT29 cells were incubated
with the compounds at 10 lM concentration. After 24 h the cells
were washed three times with cold PBS (Phosphate Buffered Sal-
ine), collected by trypsinization and centrifuged at 1000 g for
5 min. At the end the pellet was suspended in Milli-Q water, soni-
cated and the platinum content measured with a Perkin–Elmer
3100 graphite furnace atomic absorption spectrometer (GFAA).
Instrumental settings were optimised in order to yield maximum
sensitivity for platinum. The data were expressed as ng Pt per
mg of cell proteins and were the results of three independent
experiments ±SD. Protein concentration was assayed by means of
the method of Lowry [15].3. Results and discussion
3.1. Chemistry
3.1.1. IR spectra of [PtCl(bbp)]Cl (1), [PtCl2(dptdn)](H2O) (2),
[(dptdn)(dpt)Pt]Cl2(H2O) (3) complexes
In all complexes, the absorption bands in the high frequency re-
gion which originate in the heterocyclic ring of the ligands, appear
not to be metal sensitive [16].
In complex 1 N–H stretching bands sharper than those of the
free ligand are present, due to breaking of the ligand’s tautomer-
ism, indicating that the N-H group was not involved in
coordination.plex (3) and numbering scheme of atoms.
Fig. 4. 1H–1H COSY spectrum for [Pt(dptdn)(dpt)]Cl2(H2O) complex (3).
Table 1
1H NMR chemical shifts (ppm) for bbp ligand and complex 1 in DMSO-d6 at 25 C.
bbp Ligand Complex 1
NH 13.06 10.16
HF–HH 8.42 8.40
HG 8.23 8.30
HA–HD 7.82 7.80
HB–HC 7.40 7.45
Coupling constants for the complex 1: J3HF,HH–HG = 7.5; J3HA,HD–HB,HC = 3.3; (J in Hz).
Table 2
1H NMR chemical shifts (ppm) for dptdn, dpt ligands and complex 2 and 3 in DMSO-
d6 at 25 C.
dptdn Ligand dpt Ligand Complex 2 Complex 3
H60 8.94 9.01 10.49 10.40
H30 8.80 8.74 9.71 10.20
H40 8.42 8.28 8.93 9.60
SO3H 8.34–8.21 8.43 8.68
H50 7.93 8.83 8.76 8.98
Phenyl protons 7.74–7.28 7.74–7.61 7.69–7.94 8.90–7.51
Coupling constants for the complex 2: J3H60 ,H50 = 4.2; J3H30 , H40 = 8.2; J3H50 , H40 = 8.0 and
complex 3: J3H60 ,H50 = 4.2; J3H30 , H40 = 7.8; J3H50 , H40 = 7.5.
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of m(N@N) of the ligand, are shown at lower values, supporting
the notion that coordination of the triazine rings and the N atom
of the pyridyl ring to the metal ion has taken place.3.1.2. 1H NMR of [PtCl(bbp)]Cl (1), [PtCl2(dptdn)](H2O)(2) and
[(dptdn)(dpt)Pt]Cl2(H2O) (3) complexes
The reaction scheme with the numbering of protons used for
the 1H NMR is shown in Figs. 1–3. The resonances of the pyridine
groups coordinated to platinum are noticeably different from those
of non-coordinating pyridines and are shifted to higher frequencies
whilst 3JH–H coupling constants for the complex are very similar to
those of the free ligand helping the assignments. Sharpness of res-
onances gives an indication that neither oligomerization of com-
plexes nor ﬂuxionality is present. A 1H–1H COSY experiment was
carried out and the resulting spectrum for the mixed ligand com-
plex [(dptdn)(dpt)Pt]Cl2(H2O) 3 is presented in Fig. 4 which shows
the connectivities and couplings reported hereafter.
In complex 1 the two benzimidazole and pyridine rings are ex-
pected to be nearly in the same plane; the three N atoms of the li-
gand and the central Pt atom forming a good plane. The N–Hbenzimidazole signals are indicative of the complex formation.
There are two magnetically equivalent benzimidazole N–H hydro-
gens at d = 10.16 that have undergone an upﬁeld shift. Coordina-
tion is associated with the concomitant both positive and
negative induced shifts of proton resonances of aromatic rings.
According to literature data [9] these effects are due to electron
donation from the ligand to the metal via r-bond, metal electron
p-back donation, van der Waals interaction and magnetic anisot-
ropy of ring currents.
The NMR data for free ligand and the complex 1 are reported in
Table 1. The close similarity of 1H NMR data for the complex under
investigation with those reported for palladium halocomplexes
suggests a similar geometry and coordination [9].
The coordination mode of ionic mononuclear complexes 2 and 3
were analogously determined. The data for free ligand and the
complexes 2 and 3 are reported in Table 2 which closely agree with
the spectra in CD2Cl2 reported in the literature [10–11]. 13C {1H}
NMR for the complexes 2 and 3 is reported in Table 3. In the spec-
tra of complex 2 the protons of the pyridyl rings appear as a set of
Table 3
13C {1H} NMR chemical shifts (ppm) for the complex 2 and 3 in DMSO-d6.
Complex 2 Complex 3
C3 157.86 160.37
C6 157.25 156.86
C5 156.47 156.39
C60 149.03 152.25
C20–30 148.94 150.03–138.65
C40 147.25 135.75
C50 143.15 135.64
Phenyl carbons 134.82–125.49 131.08–124.49
Table 4
IC50 (lM).
HT29 cells HepG2 cells
cis-DDP 58 65
[PtCl(bbp)]Cl 22 26
[(dptdn)(dpt)Pt]Cl2(H2O) 23 24
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two phenyl rings, similar to the spectra of Zn(dpt)Cl2 complexes
[11].
Coordination of dptdn to Pt(II) causes the displacement of the
pyridyl rings resonances down ﬁeld with respect to the uncoordi-
nated ligand. Therefore the coordination of the ligand in complex 2
involves the nitrogen atoms of the pyridyl ring and N-2 of the tri-
azine ring. As reported for similar complexes of ruthenium(II) [17]
the coordination mode of the triazine ring occurs through N-2
atom, since in this case the steric hindrance between the phenyl
groups and pyridyl ring is minimised. Whilst the presence of neg-
atively charged sulphonic groups in the structure of complex 2 is
beneﬁcial for solubility of the complex, repulsive interactions
through sulphonate groups and DNA phosphate groups are proba-
bly drastically reducing the drug effectiveness towards DNA, the
complex being inactive [18].
The mixed ligand complex [(dptdn)(dpt)Pt]Cl2 3 arises from a
tentative synergic design of a complex bringing a ‘‘innocent’’ ligand
(dptdn) and an active one (dpt) together. According to a published
procedure [6] we synthesized the Pt(dpt)Cl2 complex, performing
the MTT test on HT29 and HepG2 cancer cell lines for biological
activity; being the compound active, we proceeded to synthesize
the mixed ligand complex.
The two coordinated dpt and dptdn moieties are symmetrically
bonded to the Pt(II) centre and are magnetically equivalent. The
protons of the two phenyl rings appear in the remaining part of
the spectra as two sets of multiplets, without being affected upon
complexation. Noticeably coordinated triazine and pyridyl reso-
nances are shifted to higher frequencies relative to resonances in
the free ligands. The pyridyl ring protons of the free ligand dpt
and dptdn suffer a clear downﬁeld shift on coordination; the stron-
gest shift corresponding to the H-6’ proton. The proposed struc-
tures take advantage of the X-ray structures of similar LPtCl2 and
[L2Pt]Cl2 complexes [L = substituted 3-(pyridine-20-yl)-1,2,4-tri-
azine] [6]. In our complexes we assume that the two phenyl rings
of the triazine moiety are not coplanar with the triazine plane, in
contrast the pyridyl and triazine rings are expected to be almostFig. 5. Effects of Pt(II) complexes or cis-DDP on HT29 and HepG2 cell viability. Cells were
was estimated by MTT assay, as reported in Methods. Results are indicated as the perce
±S.D. of six independent experiments performed in triplicate.coplanar. The mixed ligand complex 3 is characterised by an over-
all positive charge and four non-labile N bonds.
3.2. Biology
3.2.1. Platinum complexes impair HT29 and HepG2 cell viability
To examine the effect of the novel mononuclear platinum com-
plexes, in comparison with that exerted by cisplatin, on human
HT29 colorectal carcinoma and HepG2 hepatocarcinoma cells,
monolayer cultures were treated for 24 h with various concentra-
tions (5–50 lM) of the drugs and the viability was evaluated by
MTT assay to measure mitochondrial enzyme activity, as reported
in Section 2 [13]. Fig. 5 shows that both [PtCl(bbp)]Cl 1 and
[(dptdn)(dpt)Pt]Cl2(H2O) 3 clearly reduced cell viability in a
dose-dependent manner and their activity was higher than that
shown by cisplatin. In particular, at the concentration of 50 lM
the reduction of cell viability, induced by the two compounds,
was at a range of about 60–70%. On the contrary, the
[PtCl2(dptdn)](H2O) 2 complex was almost inefﬁcacious. The
marked cytotoxic activity of complexes 1 and 3 was conﬁrmed
by the values of IC50, clearly lower than that of cisplatin (Table 4).
Experiments performed to assay the activity of free ligands used
to synthesize the Pt(II) complexes demonstrated that these ligands
were unable to exert any inhibitory activity (not shown). Fig. 6 re-
ports the effects of the two active Pt(II) complexes or cisplatin on
HT29 cell cycle distribution as determined by ﬂow cytometric
analysis after staining of DNA with propidium iodide. Complexes
1 and 3, at concentration 25 lM induced after 24 h of treatment
a marked accumulation of cells (about 40%) in the subG0/G1 phase
of cell cycle which is representative of cells with fragmented DNA.
At this concentration cisplatin was less active. Similar results were
obtained with HepG2 cells (not shown). Furthermore, under the
same experimental conditions, the study of mitochondrial trans-
membrane potential (Dwm), using the lipophilic cationic ﬂuoro-
chrome DiOC6 and ﬂow cytometry analysis (Fig. 7), shows that
the two active compounds 1 and 3 induced in HT29 cells a signif-
icant decrease in DiOC6 uptake, indicating a loss ofDwm. The mem-
brane potential decreased by about 40% in the presence of the two
compounds and by about 20% with cisplatin.
We next assessed whether the cytotoxic effect of the active
compounds was associated with the induction of apoptosis. Results
of the Hoechst 33258 staining performed in HT29 cells treatedtreated for 24 h with the compounds, at the indicated concentrations. Cell viability
ntage of viable cells with respect to untreated controls. Data represent the average
Fig. 6. Effects of Pt(II) complexes or cis-DDP on cell cycle distribution. Flow cytometric analysis of cell cycle distribution of HT29 cells after incubation with 25 lM of the
compounds, for 24 h. Cells were stained with propidium iodide as described in Section 2. The percentage of cells in the different phases of the cycle was calculated using
Expo32 software. Data are representative of four experiments with similar results.
Fig. 7. Effects of Pt(II) complexes or cis-DDP on dissipation of mitocondrial transmembrane potential (Dwm) in HT29 cells. After treatment with 25 lM of the compounds for
24 h cells were stained with the lipophilic cationic ﬂuorochrome DiOC6 as reported in Methods. Quantiﬁcation of Dwm was performed by ﬂow citometry using Expo32
software. Data are representative of three separate experiments with similar results.
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Fig. 8. Nuclear staining to evaluate the apoptotic effects of Pt(II) complexes. HT29 cells were treated for 24 h with 25 lM of Pt(II) complexes and morphological changes were
visualised under a ﬂuorescence microscope after Hoechst 33258 staining, as described in Section 2. Data shown are representative of three experiments with similar results.
Fig. 9. Platinum intracellular accumulation after incubation with Pt(II) complexes
or cis-DDP. HT29 cells were treated for 24 h with the compounds at 10 lM
concentration. At the end intracellular Pt was quantiﬁed by GFAA as described in
Methods. The results are representative of three independent experiments.
214 S. Rubino et al. / Inorganica Chimica Acta 370 (2011) 207–214with 25 lM of complexes 1 and 3, for 24 h, demonstrated apoptotic
features such as nuclear shrinkage, chromatin condensation or
fragmentation (Fig. 8).
In order to better understand the cytotoxic activity of the new
mononuclear platinum complexes, with respect to cisplatin, we
have determined cellular platinum uptake on HT29 cells after
24 h continuous exposure with 10 lM compounds. The amount
of intracellular platinum, evaluated by GFAA, for Pt(II) complexes
gave similar values to those obtained for cisplatin (Fig. 9). There-
fore, these results demonstrated that the different cytotoxic effects
exerted by the new Pt(II) complexes and cisplatin could not be ex-
plained in terms of different platinum uptake.
4. Conclusions
A series of new Pt(II) ‘‘non classical’’ mononuclear complexes 1,
2 and 3, both ionic 1 and 3 and neutral 2 with heterocyclic ligands
have been synthesized and characterised. The coordination of Pt(II)
in 1 has been advanced to take place through three N-atoms, one of
pyridine and two of benzimidazole moieties, that originate a highly
ionic symmetric complex. The neutral asymmetric complex 2 con-
tains a bifunctional PtCl2 moiety bonded in a cis position to two N
atoms of heterocyclic ligand with a cisplatin similar coordination.
The ionic complex 3 contains two different heterocyclic dptdn
and dpt ligands with Pt(II) ion bonded to four N atoms of the li-
gands forming a square planar complex. Two of the novel mononu-
clear platinum complexes, 1 and 3, synthesized in our laboratory,
show a potent cytotoxic activity in HT29 and HepG2 cancer cell
lines. The marked cytotoxic activity of 1 and 3 complexes was con-
ﬁrmed by the values of IC50, clearly lower than that of cisplatin. On
the contrary, the complex 2 was almost ineffective. Flow cytomet-
ric analysis and ﬂuorescence microscopy demonstrated that the
complexes 1 and 3 induced apoptotic cells death as evidenced by
a marked accumulation of cells in the subG0/G1 phase of cell cycle,
loss of mitochondrial transmembrane potential (Dwm) andmorphological changes, respectively. A study on intracellular Pt
uptake in HT29 cell line, that is the amount of intracellular metal
corresponding to the quantity of drug present inside the cell, has
been also performed, showing that the different in vitro cytotoxic
effects of the novel complexes reported in this work and of cis-
platin could not be explained in terms of platinum uptake, but
based on different phamacodynamics. On the basis of the planar
structure of the compounds and of their positive charge, we
hypothesise that the exerted cytotoxic activity can explained by
possible intercalative interactions with DNA.
This observation suggests that the mechanism underlying the
antitumor activity of complexes 1 and 3 might be different from
that of cisplatin and very close to those reported by us for polynu-
clear ionic platinum complexes with triazine derived heterocycles
[19,20].
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